View Filing Data

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Jan. 31, 2014	Mar. 13, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jan. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Trading Symbol	ADXS
Entity Common Stock, Shares Outstanding		14,016,344
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Current Fiscal Year End Date	--10-31
Entity Filer Category	Smaller Reporting Company

BALANCE SHEETS - USD ($)	Jan. 31, 2014	Oct. 31, 2013
Current Assets:
Cash	$ 15,959,266	$ 20,552,062
Prepaid Expenses	14,139	31,255
Other Current Assets	83,182	8,182
Deferred Expenses - current	148,882	218,007
Total Current Assets	16,205,469	20,809,506
Deferred Expenses - long term	93,149	129,041
Property and Equipment (net of accumulated depreciation)	98,077	80,385
Intangible Assets (net of accumulated amortization)	2,499,044	2,528,551
Other Assets	38,438	38,438
TOTAL ASSETS	18,934,177	23,585,921
Current Liabilities:
Accounts Payable	2,305,859	3,841,771
Accrued Expenses	1,024,269	869,260
Short Term Convertible Notes and Fair Value of Embedded Derivative	62,882	62,882
Notes Payable - Officer	165,097	163,132
Total Current Liabilities	3,558,107	4,937,045
Common Stock Warrant Liability	516,268	646,734
Total Liabilities	4,074,375	5,583,779
Commitments and Contingencies
Shareholders’ Equity:
Common Stock - $0.001 par value; authorized 25,000,000 shares, issued and outstanding 14,009,475 at January 31, 2014 and 13,719,861 at October 31, 2013.	14,009	13,720
Additional Paid-In Capital	90,499,008	88,454,245
Deficit accumulated during the Development Stage	(75,653,215)	(70,465,823)
Total Shareholders’ Equity	14,859,802	18,002,142
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 18,934,177	$ 23,585,921

BALANCE SHEETS [Parenthetical] - $ / shares	Jan. 31, 2014	Oct. 31, 2013
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	14,009,475	13,719,861
Common stock, shares outstanding	14,009,475	13,719,861

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		143 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014
Revenue	$ 0	$ 0	$ 1,863,343
Operating Expenses
Research and Development Expenses	1,559,867	979,103	36,984,690
General and Administrative Expenses	4,397,836	1,201,951	40,337,959
Total Operating Expenses	5,957,703	2,181,054	77,322,649
Loss from Operations	(5,957,703)	(2,181,054)	(75,459,306)
Other Income (Expense):
Interest Expense	(2,015)	(361,176)	(15,975,627)
Other Income (Expense)	8,572	(19,898)	197,405
(Loss) Gain on Note Retirement	6,243	152,491	(4,442,026)
Net changes in Fair Value of Common Stock Warrant Liability and Embedded Derivative Liability	131,948	(4,023,599)	19,669,780
Loss before Benefit for Income Taxes	(5,812,955)	(6,433,236)	(76,009,774)
Income Tax Benefit	625,563	725,190	3,278,013
Net Loss	(5,187,392)	(5,708,046)	(72,731,761)
Dividends Attributable to Preferred Shares	0	185,000	2,877,570
Net Loss Applicable to Common Stock	$ (5,187,392)	$ (5,893,046)	$ (75,609,331)
Net Loss Per Share, Basic and Diluted	$ (0.37)	$ (1.65)
Weighted Average Number of Shares Outstanding, Basic and Diluted	13,842,144	3,565,032

STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		143 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014
OPERATING ACTIVITIES
Net Loss	$ (5,187,392)	$ (5,708,046)	$ (72,731,761)
Adjustments to reconcile Net Loss to net cash used in operating activities:
Non-cash charges to consultants and employees for options and stock	1,602,423	369,923	11,128,461
Amortization of deferred financing costs	0	15,291	424,767
Amortization of discount on convertible promissory notes	0	7,979	2,728,769
Impairment of intangible assets	0	0	26,087
Non-cash interest expense	51	328,187	12,339,263
(Gain) Loss on change in value of warrants and embedded derivative	(131,948)	4,023,599	(19,669,780)
Warrant Expense	1,482	3,274	889,586
Settlement Expense	34,125	131,965	1,063,460
Employee Stock Purchase Plan	5,371	5,481	51,727
Value of penalty shares issued	0	0	149,276
Depreciation expense	6,903	4,592	235,650
Amortization expense of intangibles	41,934	38,703	943,913
Write off of intangible assets	0	0	33,211
Interest Income	0	0	267
(Gain) Loss on note retirement	(6,243)	(152,491)	4,442,026
Changes in operating assets and liabilities :
Decrease (Increase) in prepaid expenses	17,116	14,128	(27,068)
(Increase) in other current assets	(75,000)	(75,000)	(83,182)
(Increase) in other assets	0	0	(132,271)
Decrease in deferred expenses	105,018	74,943	265,698
Increase (decrease) in accounts payable and accrued expenses	(1,371,578)	(225,360)	9,991,782
(Decrease) in deferred rent	0	(4,803)	0
Increase in interest payable	1,964	9,530	26,297
Net cash used in operating activities	(4,955,774)	(1,138,105)	(47,903,822)
INVESTING ACTIVITIES
Cash paid on acquisition of Great Expectations	0	0	(44,940)
Proceeds from sale of property and equipment	0	0	3,000
Purchase of property and equipment	(24,595)	0	(291,148)
Cost of intangible assets	(12,427)	(43,709)	(3,507,205)
Net cash used in Investing Activities	(37,022)	(43,709)	(3,840,293)
FINANCING ACTIVITIES
Proceeds from convertible notes	0	753,500	20,827,900
Repayment of convertible notes	0	0	(2,339,829)
(Increase) in deferred offering expenses	0	(3,500)	(114,000)
Cash paid for deferred financing costs	0	0	(651,412)
Proceeds from notes payable	0	0	250,000
Proceeds from Officer Loan	0	3,800	1,455,685
Repayment of Officer Loan	0	0	(1,323,833)
Net proceeds from issuance of Preferred Stock	0	0	8,610,499
Payment on cancellation of warrants	0	0	(600,000)
Proceeds from exercise of warrants	0	0	1,761,210
Net proceeds of issuance of common stock	400,000	427,882	39,827,161
Net cash provided by Financing Activities	400,000	1,181,682	67,703,381
Net increase (decrease) in cash	(4,592,796)	(132)	15,959,266
Cash at beginning of period	20,552,062	232	0
Cash at end of period	$ 15,959,266	$ 100	$ 15,959,266

Supplemental Disclosures of Cash Flow Information - USD ($)	3 Months Ended		143 Months Ended
	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014
Cash paid for Interest	$ 0	$ 188	$ 914,005
Supplemental Schedule of Non-cash Investing and Financing Activities
Equipment acquired under notes payable	0	0	45,580
Common Stock issued to Founders	0	0	40
Notes payable and accrued interest converted to Preferred Stock	0	0	15,969
Stock dividend on Preferred Stock	0	0	43,884
Accounts Payable from vendors settled with Common Stock	0	0	3,249,990
Accounts Payable from consultants settled with Common Stock	3,000	0	893,555
Notes payable and embedded derivative liabilities converted to Common Stock	0	765,599	19,806,369
Intangible assets acquired with notes payable	0	0	360,000
Intangible assets acquired with Common Stock	0	0	70,000
Debt discount in connection with recording the original value of the embedded derivative liability	0	0	6,473,385
Allocation of the original secured convertible debentures to warrants	0	0	214,950
Allocation of the warrants on convertible notes as debt discount	0	0	3,001,806
Cancellation of Note Receivable in connection with Preferred Stock Redemption	0	0	(13,684,584)
Note receivable in connection with exercise of warrants	0	0	9,998,210
Common Stock issued in exchange for warrants	0	0	2,443,296
Warrants issued in connection with issuance of Common Stock	0	0	2,023,247
Warrants issued in connection with issuance of Preferred Stock	$ 0	$ 0	$ 3,587,625

ORGANIZATION

3 Months Ended

Jan. 31, 2014

Nature Of Operations and Basis Of Presentation [Abstract]

Nature Of Operations and Basis Of Presentation [Text Block]

1. ORGANIZATION

Advaxis Inc. (the “Company”) is a clinical development stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm- LLO cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (“Lm”), bioengineered to secrete antigen/adjuvant fusion proteins. These Lm -LLO strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Other immunotherapies may employ individual elements of the Company’s comprehensive approach, but, to its knowledge, none combine all of these elements together in a single, easily administered, well-tolerated yet comprehensive immunotherapy.

ADXS-HPV is Advaxis’ lead immunotherapy for the treatment of human papilloma virus (“HPV”)-associated cancers. The Company completed a Phase 2 study in 110 patients with recurrent cervical cancer in India that demonstrated a manageable safety profile, improved survival and objective tumor responses, providing the rationale to advance this immunotherapy to registrational Phase 3 trials for the treatment of women with recurrent cervical cancer. ADXS-HPV is being evaluated in three ongoing clinical trials for HPV-associated cancer as follows: locally advanced cervical cancer (with the Gynecologic Oncology Group (“GOG”), largely underwritten by the National Cancer Institute (“NCI”); head and neck cancer (with the Ichan School of Medicine at Mount Sinai (“MSSM”); (U.S); and anal cancer (Brown University, Oncology Group (“BrUOG”), U.S.). In addition, the Company has developed immunotherapies for prostate cancer and HER2 overexpressing cancers (such as breast, gastric and other cancers in humans and osteosarcoma in canines). Over fifteen distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

Since inception in 2002, the Company has focused its development efforts on understanding its technology and establishing a drug development pipeline that incorporates this technology into therapeutic cancer immunotherapies, currently those targeting HPV-associated cancer (cervical cancer, head and neck cancer and anal cancer), prostate cancer, and HER2 overexpressing cancers. Although no immunotherapies have been commercialized to date, research and development and investment continues to be placed behind the pipeline and the advancement of this technology. Pipeline development and the further exploration of the technology for advancement entail risk and expense. The Company anticipates that its ongoing operational costs will increase significantly as it continues conducting its clinical development program.

Liquidity and Financial Condition

The Company’s products are being developed and have not generated significant revenues. As a result, the Company has suffered recurring losses. These losses are expected to continue for an extended period of time. The Company has successfully completed a public offering of its common stock in October 2013, resulting in approximately $24 million in net proceeds. The Company believes its current cash position is sufficient to fund its business plan for the next eighteen months.

The Company recognizes it will need to raise additional capital over and above the amount raised during October 2013 in order to continue to execute its business plan. Subsequent to January 31, 2014, the Company plans to continue to raise additional funds through the sales of equity securities. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its business plan, extend payables and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

3 Months Ended

Jan. 31, 2014

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation - Unaudited Interim Financial Information

The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim financial statements should be read in conjunction with the financial statements of the Company for the year ended October 31, 2013 and notes thereto contained in the Company’s annual report on Form 10-K for the year ended October 31, 2013, as filed with the SEC on January 29, 2014.

Estimates

The preparation of financial statements in accordance with U.S. Generally Accepted Accounting Principles (GAAP) involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from estimates.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $ 15.2 million is subject to credit risk at January 31, 2014. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Fair Value of Financial Instruments

The carrying amounts of financial instruments, including cash, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Net Loss per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.

	As of January 31,
	2014		2013
Warrants		4,360,441		1,001,236
Stock Options		467,923		355,890
Convertible Debt (using the if-converted method)		3,354		390,566
Total		4,831,718		1,747,692

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

The above stock-based compensation for employees, executives and directors is measured based on the fair market value of the shares issued on the date of grant and is to be recognized over the requisite service period in both research and development expenses and general and administrative expenses on the statement of operations.

Recent Accounting Pronouncements

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

PROPERTY AND EQUIPMENT

3 Months Ended

Jan. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

3. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	January 31, 2014 (Unaudited)		October 31, 2013
Laboratory Equipment	$	333,727	$	309,132
Accumulated Depreciation		(235,650)		(228,747)
Net Property and Equipment	$	98,077	$	80,385

Depreciation expense for the three months ended January 31, 2014 and 2013, and the period from March 1, 2002 (inception) to January 31, 2014, was $6,903, $4,592 and $235,650, respectively.

INTANGIBLE ASSETS

3 Months Ended

Jan. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Disclosure [Text Block]

4. INTANGIBLE ASSETS

Under the Penn license agreements, the Company is billed actual patent expenses as they are passed through from Penn and are billed directly from our patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:

	January 31, 2014 (Unaudited)		October 31, 2013
License	$	651,992	$	651,992
Patents		2,708,970		2,696,543
Total intangibles		3,360,962		3,348,535
Accumulated Amortization		(861,918)		(819,984)
Intangible Assets	$	2,499,044	$	2,528,551

The expirations of the existing patents range from 2014 to 2023 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. No patent applications with future value were abandoned or expired and charged to expense in the three months ended January 31, 2014 or 2013. Amortization expense for licensed technology and capitalized patent costs are included in general and administrative expenses and aggregated $41,934, $38,703 and $943,913 for the three months ended January 31, 2014 and 2013 and for the period from March 1, 2002 (inception) to January 31, 2014, respectively.

Estimated amortization expense for the next five years is as follows:

Year ended October 31,

2014 (Remaining)		125,500
2015		167,500
2016		167,500
2017		167,500
2018		167,500

ACCRUED EXPENSES:

3 Months Ended

Jan. 31, 2014

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

5. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses:

	January 31, 2014		October 31,
	(Unaudited)		2013
Salaries and Other Compensation	$	721,672	$	752,248
Consultants		2,000		2,000
Legal		15,000		15,000
Withholding Taxes Payable		185,585		-
Share Purchase		100,012		100,012
	$	1,024,269	$	869,260

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE

3 Months Ended

Jan. 31, 2014

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

6. SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE

As of January 31, 2014 and October 31, 2013, the Company had approximately $63,000 in principal outstanding on its junior subordinated convertible promissory notes that are currently overdue and are recorded as current liabilities on our balance sheet at January 31, 2014 and October 31, 2013.

NOTES PAYABLE- FORMER OFFICER:

3 Months Ended

Jan. 31, 2014

Notes Payable Officer [Abstract]

Notes Payable Officer [Text Block]

7. NOTES PAYABLE- FORMER OFFICER:

As of October 31, 2013, the Company owed $163,132 in principal and accrued interest to its former Chairman. During the three months ended January 31, 2014 and January 31, 2013, the Company incurred approximately $5,000 and $9,500 in interest on these notes respectively. On February 4, 2014, the Company paid Mr. Moore $168,280 in principal and accrued interest, in full satisfaction of these Notes.

DERIVATIVE INSTRUMENTS

3 Months Ended

Jan. 31, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

8. DERIVATIVE INSTRUMENTS

Warrants

A summary of changes in warrants for the three months ended January 31, 2014 is as follows:

	Number of	Weighted-Average
	Warrants	Exercise Price
Outstanding Warrants at October 31, 2013:	4,265,262	$	6.71
Issued	101,704	$	5.58
Exercised	-		-
Expired	(6,525)	$	21.25
Outstanding Warrants at January 31, 2014	4,360,441	$	6.66

At January 31, 2014 and October 31, 2013, the Company had approximately 3.8 million of its total 4.4 million outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders’ equity section of the balance sheet. The equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions. During the three months ended January 31, 2014, the Company issued 100,000 equity warrants to an entity pursuant to a Stock Purchase Agreement. These warrants expire in December 2018 and have an exercise price of $5.52.

At January 31, 2014 and October 31, 2013, the Company had approximately 0.6 million of its total 4.4 million outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of January 31, 2014, was approximately $0.5 million. The fair value of the warrant liability, as of October 31, 2013 was approximately $0.6 million. In fair valuing the warrant liability, at January 31, 2014 and October 31, 2013, the Company used the following inputs in its BSM Model:

	01/31/2014			10/31/2013

Exercise Price:	$	2.76-21.25		$	2.76-21.25

Stock Price	$	4.49		$	3.74

Expected term:		41-1203 days			61-1371 days

Volatility %		91%-186	%		99%-186	%

Risk Free Rate:		.035%-.69	%		.035%-.94	%

Warrant Liability/Embedded Derivative Liability

Warrant Liability

As of January 31, 2014, the Company had approximately 561,000 of its total approximately 4.4 million total warrants classified as liabilities (liability warrants). Of these 561,000 liability warrants, approximately 283,000 warrants are outstanding and 278,000 warrants are exchange warrants – nonexercisable. The Company utilizes the Black-Scholes Model ( “BSM Model ”) to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM Model, to account for the various possibilities that could occur due to changes in the inputs to the BSM Model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. At January 31, 2014, approximately 204,000 of the 561,000 liability warrants are subject to weighted-average anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

As of October 31, 2013, the Company had approximately 565,000 of its total approximately 4.3 million total warrants classified as liabilities (liability warrants). Of these 565,000 liability warrants, approximately 287,000 warrants are outstanding and 278,000 warrants are exchange warrants – nonexercisable. The Company utilizes the BSM Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM Model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. At October 31, 2013, approximately 203,000 of the 565,000 liability warrants are subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

At January 31, 2014 and October 31, 2013, the fair value of the warrant liability was approximately $516,000 and $647,000, respectively. For the three months ended January 31, 2014 and January 31, 2013, the Company reported income of approximately $132,000 and a loss of approximately $2.9 million, respectively, due to changes in the fair value of the warrant liability.

Warrants with anti-dilution provisions

Some of the Company’s warrants (approximately 204,000) contain anti-dilution provisions originally set at $25.00 with a term of five years. As of January 31, 2014, these warrants had an exercise price of approximately $9.16. As of October 31, 2013, these warrants had an exercise price of approximately $9.26. If the Company issues any common stock , except for exempt issuances as defined in the warrant agreement for consideration less than the exercise price then the exercise price and the amount of warrant shares available would be adjusted to a new price and amount of shares per the “ weighted average” formula included in the warrant agreement. For the three months ended January 31, 2014, this anti-dilution provision required the Company to issue approximately 1,700 additional warrant shares; and the exercise price to be lowered to $9.16. Any future financial offering or instrument issuance below the current exercise price of $9.16 will cause further anti-dilution and re-pricing provisions in approximately 204,000 of its total outstanding warrants.

For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $9.16 and $7.50, weighting the possibility of warrants being exercised at $9.16 between 40% and 50% and warrants being exercised at $7.50 between 60% and 50%.

As of January 31, 2014, there were outstanding warrants to purchase 4,360,441 shares of the Company’s Common Stock including exchange warrants - nonexercisable to purchase 278,329 shares of the Company’s Common Stock with exercise prices ranging from $2.76 to $21.25 per share.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

STOCK OPTIONS:

3 Months Ended

Jan. 31, 2014

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Stock Options Disclosure [Text Block]

9. STOCK OPTIONS:

A summary of changes in the stock option plan for three months ended January 31, 2014 is as follows:

	Number of		Weighted-Average
	Options		Exercise Price
Outstanding at October 31, 2013:		467,923	$	15.86
Granted		-	$	-
Exercised		-	$	-
Expired		-	$	-
Outstanding at January 31, 2014		467,923	$	15.86
Vested and Exercisable at January 31, 2014		403,567	$	16.22

Total compensation cost related to our outstanding stock options, recognized in the statement of operations for the three months ended January 31, 2014, was $257,486 of which $90,380 was included in research and development expenses and $167,106 was included in general and administrative expenses. For the three months ended January 31, 2013 compensation cost was approximately $263,000, of which approximately $110,000 was included in research and development expenses and approximately $153,000 was included in general and administrative expenses.

There were no options granted during the three months ended January 31, 2014 or 2013.

As of January 31, 2014, there was approximately $947,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining average vesting period of 0.87 years.

The aggregate intrinsic value of these outstanding options, as of January 31, 2014, was approximately $6,880.

COMMITMENTS AND CONTINGENCIES:

3 Months Ended

Jan. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

10. COMMITMENTS AND CONTINGENCIES :

Employment Agreements

On December 19, 2013, the Company and each of Daniel J. O’Connor, Chief Executive Officer and President, Gregory T. Mayes, Executive Vice President and Chief Operating Officer, Mark J. Rosenblum, Senior Vice President, Chief Financial Officer and Secretary, Robert G. Petit, Executive Vice President and Chief Scientific Officer, and Chris L. French, Vice President and Executive Director, Medical Affairs, of the Company (each, an “Executive”), voluntarily entered into an amendment (each, an “Amendment” and collectively, the “Amendments”) to their respective employment agreements (each, an “Employment Agreement”).

Under the terms of each Amendment, all of the Executives voluntarily agreed to utilize a percentage of their base salary for stock compensation. Common Stock of the Company (“Common Stock”) will be acquired by each Executive based on the fair market value of the Common Stock on the date of acquisition. The allocation between the cash and equity components of each Executive’s base salary is as follows:

	% of base salary	% of base salary
Executive	in cash	in stock
Daniel J. O’Connor	75.0	25.0
Gregory T. Mayes, III	92.5	7.5
Mark J. Rosenblum	92.5	7.5
Robert G. Petit	91.5	8.5
Chris L. French	95.0	5.0

The stock compensation will be acquired by the Executives on the last business day of each fiscal quarter of the Company in accordance with the terms and provisions of the Company's 2011 Omnibus Incentive Plan. Accordingly, the Company recorded stock compensation expense of approximately $18,000 on the statement of operations representing 4,017 shares of our common stock (3,134 shares on a net basis after employee payroll taxes).

The Amendments entered into by and between the Company and Mr. O’Connor, Mr. Rosenblum, Mr. Petit and Ms. French also clarify that each such Executive’s permission to purchase discounted Common Stock in any capital raise conducted by the Company shall only be to the extent permitted by, and on terms consistent with, the Company's 2011 Omnibus Incentive Plan, applicable law and the rules and regulations of NASDAQ (or such other applicable exchange).

Stock Awards

In December 2013, the Company granted stock awards and restricted stock units (RSUs) to employees, executive officers and directors under the 2011 Omnibus Incentive Plan. These awards include the employment agreement amounts noted above in addition to the following:

⋅	Management Team Bonuses: Executive officers received a portion of their year-end performance bonus (with a total fair market value of approximately $129,000) in the aggregate amount of 31,846 shares of the Company’s Common Stock.

⋅

Equity grant to executive officers: The Company granted 525,000 shares of its Common Stock to its executive officers. Of these shares, 20% (105,000 shares) vested immediately, with a total fair market value of $423,150, and were issued and recorded as a charge to income during the current period. The remaining 80% of the grant (420,000 shares) represent restricted stock units (RSUs) and are to vest in equal installments over twelve quarters such that 100% of the RSUs have vested by the third anniversary of the grant date. The first quarterly vesting, totaling an aggregate of 35,000 shares of our common stock are subject to availability of shares under the 2011 Omnibus Incentive Plan and are subject to forfeiture under certain conditions. Currently, these shares are not available under the 2011 Omnibus Plan and accordingly, have not been issued.

⋅

Equity grant to non-executive employees: The Company granted approximately $101,250 of the aggregate base salary compensation, to be issued in the form of Common Stock to its non-executive employees. Of this grant, 20% (an aggregate value of $20,250) vested immediately and 5,025 shares of common stock were issued to non-executive employees. The remaining 80% of the grant (shares with an aggregate value of $81,000) represent restricted stock units (RSUs) and are to vest in equal installments over twelve quarters such that 100% of the RSUs have vested by the third anniversary of the grant date. The first quarterly vesting, totaled a fair market value of $7,520 and was recorded as a charge to income, representing 1,675 shares of our common stock, which remain unissued as of January 31, 2014. All of these non-executive equity grants are currently available under the 2011 Omnibus Incentive Plan.

The Company will recognize the fair value of those vested shares, in the statement of operations in the period earned.

Director Compensation

During December 2013, the Board of Directors deemed it advisable and in the best interests of the Company to issue shares of stock in compensation for all 2013 Board of Director committee meetings and to cancel any options designated for issuance related to those 2013 committee and board meetings and to further issue shares of stock for all fiscal years 2013 through 2015 Board of Director committee meetings in the aggregate amount of 50,000 shares of restricted stock units (RSU’s) to each non-employee director (excluding Mr. Moore). The RSU grant will vest quarterly over three years such that 100% of the RSU will be vested on the third anniversary date (December 2016).

During December 2013, the Board of Directors deemed it advisable and in the best interests of the Company to amend a certain provision of the Consulting Agreement with Mr. Moore, which took effect August 19, 2013 and issue 37,500 restricted stock units (RSU’s). The RSU grant will vest quarterly over three years such that 100% of the RSU will be vested on the third anniversary date (December 2016).

Currently, these director compensation shares are not available under the 2011 Omnibus Incentive Plan and accordingly, the Company did not record a charge to income.

Legal Proceedings

On August 19, 2013, the Company entered into an agreement with Maxim Group LLC, or Maxim, to terminate a July 2012 engagement agreement between the parties, pursuant to which Maxim asserted claims for unpaid fees related to the introduction of investors to us and services provided. As consideration for terminating the agreement, the Company agreed to pay Maxim in monthly installment payments in either cash or shares of Common Stock, and issued a warrant to purchase 30,154 shares of our Common Stock at an exercise price of $ 4.90 per share. On September 27, 2013, the Company issued 158,385 shares of Common Stock to satisfy all remaining amounts owed under this agreement. Maxim rejected the delivery of these 158,385 shares and claimed that the Company may not prepay its obligations under the agreement notwithstanding any language to the contrary in the agreement.

Upon the completion of the Company’s public offering in October, 2013 the Company paid Maxim $ 150,000 and commenced final settlement of the disputed amounts owed. On or about November 14, 2013, Maxim initiated a proceeding by confession of judgment in New York State Court to recover monies it believes Advaxis owes it under the Termination Agreement in the amount of approximately $ 484,710. On November 15, 2013 the New York County Clerk’s office entered a judgment in favor of Maxim. On or about November 22, 2013 Maxim mailed a Notice of Entry To Advaxis and the parties decided to settle the dispute without any admission of liability or wrongdoing. On December 18, 2013, the 158,385 shares were cancelled. On December 23, 2013 the parties executed a Settlement Agreement and Release. On December 27, 2013, the Company paid Maxim $ 285,000 in final settlement of all matters related to their claim.

The Company is from time to time involved in legal proceedings in the ordinary course of our business. The Company does not believe that any of these claims and proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations.

University of Pennsylvania

On May 10, 2010, the Company entered into a second amendment to the Penn license agreement pursuant to which it acquired exclusive licenses related to its proprietary Listeria vaccine technology. As part of this amendment the Company exercised its option for the rights to additional patent dockets and agreed to pay historical patent costs incurred by Penn. As of October 31, 2013, the Company owed Penn approximately $325,000. During the first quarter ended January 31, 2014, the Company paid Penn approximately $306,000 under all licensing agreements. As of January 31, 2014, the Company owed Penn approximately $127,000 under all licensing agreements. As of January 31, 2014, Penn owned 28,468 shares of the Company’s Common Stock.

Separation Agreement

On March 6, 2013, the Company announced the departure of Dr. John Rothman, the Company’s former Executive Vice President of Clinical and Scientific Operations, effective March 1, 2013. On March 20, 2013, the Company entered into a Separation Agreement and General Release with Dr. Rothman, pursuant to which Dr. Rothman released the Company from all claims and agreed to continue to assist the Company as a consultant until February 28, 2014 in exchange for (i) being compensated on an hourly basis for certain project assignments as requested by the Company, (ii) receiving an aggregate of approximately $275,000, paid in installments over the course of the one year consulting period, and (iii) all of the options to purchase shares of the Company’s common stock held by Dr. Rothman being fully vested with the exercise period of such options being extended until March 1, 2015.

As of March 10, 2014, there are no remaining payments due under the Separation Agreement and General Release.

Consulting Agreement; Debt Conversion/Repayment

On August 19, 2013, the Company entered into a consulting agreement with Mr. Moore, pursuant to which Mr. Moore will continue to assist the Company with the development of its veterinary program in exchange for (i) receiving an aggregate of approximately $ 350,000 , paid in installments over the course of the one year consulting period, and (ii) reimbursement by the Company for any costs associated with or incurred by Mr. Moore for participation in a group health plan and (iii) a grant of 37,500 restricted stock units (RSU’s) that will vest quarterly over three years. The term for this consulting agreement is one year.

On September 26, 2013, the Company entered into a debt conversion and repayment agreement with Thomas A Moore, a Director of the Company and our former Chief Executive Officer, with respect to the repayment and partial conversion of amounts owed to Mr. Moore under outstanding promissory notes issued pursuant to that certain Note Purchase Agreement dated September 22, 2008, as amended from time to time. The Company refers to these outstanding notes as the Moore Notes. As provided in the agreement, following the closing of the October 22, 2013 public offering: (a) the Company paid Mr. Moore $ 100,000 in cash as partial repayment of the Moore Notes, (b) the Company converted one-half of the remaining balance (approximately $162,132) using the same terms as securities being offered and sold in the October 22, 2013 offering and issued Mr. Moore 40,783 shares of our Common Stock and a five-year warrant to purchase 20,392 shares of our Common Stock at an exercise price of $5.00 per share on October 31, 2013 and (c) within three months of the closing of the offering, the Company will pay Mr. Moore in cash the then remaining outstanding balance under the Moore Notes (approximately $163,132). The Company paid Mr. Moore $168,280, on February 4, 2014, fully satisfying its obligations under the Moore Notes, which no longer remain outstanding.

Sale of Net Operating Losses (NOLs)

The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses under the State of New Jersey NOL Transfer Program. In January 2014, the Company received a net cash amount of $ 625,563 from the sale of its state NOLs and research and development tax credits for the periods ended October 31, 2010 and 2011. These proceeds were received in January 2014.

SHAREHOLDERS' EQUITY

3 Months Ended

Jan. 31, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

11. SHAREHOLDERS’ EQUITY

Equity Enhancement Program

On September 27, 2013, the Company notified Hanover that it irrevocably commits to suspend any draw-downs under the Purchase Agreement without the prior written consent of Aegis Capital Corp. for a six month period from the closing. During the three months ended January 31, 2014, the Company and Hanover agreed to terminate the Common Stock Purchase Agreement in exchange for the issuance of 7,080 shares of its Common Stock.

Stock Purchase Agreement

During the three months ended January 31, 2014, the Company received proceeds of $400,000 under a Stock Purchase Agreement with Global BioPharma Inc. (GBP). During February 2014, the Company issued GBP 108,724 shares of our Common Stock under the Stock Purchase Agreement.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

FAIR VALUE

3 Months Ended

Jan. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

12. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

⋅ Level 1 — Quoted prices in active markets for identical assets or liabilities

⋅ Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities

⋅ Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities

The following table provides the liabilities carried at fair value measured on a recurring basis as of January 31, 2014:

January 31, 2014	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from October 2012 through August 2017	$	-	$	$	516,268	$	516,268

October 31, 2013	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from October 2012 through August 2017	$	-	$	$	646,734	$	646,734

Common stock warrant liability:

	January 31, 2014 (Unaudited)
Beginning balance: October 31, 2013	$	646,734
Issuance of additional warrants due to anti-dilution provisions		1,482
Change in fair value		(131,948)

Balance at January 31, 2014	$	516,268

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

SUBSEQUENT EVENTS

3 Months Ended

Jan. 31, 2014

Subsequent Events [Abstract]

Subsequent Events [Text Block]

13. SUBSEQUENT EVENTS

Issuance of shares to Executives

On February 5, 2014, pursuant to amendments to their employment agreements, the Company’s executives acquired 4,017 shares of common stock, utilizing a percentage of their base salaries (See Footnote 10: Commitments and Contingencies, Employment Agreements). Accordingly, the Company recorded stock compensation expense of approximately $18,000 (representing the aggregate value of total shares acquired) on the statement of operations during the quarter and issued 3,134 shares (on a net basis after employee payroll taxes) of our common stock during February 2014.

Warrant Exercise

On February 21, 2014, an accredited investor exercised 50 warrants at an exercise price of $5.00 per warrant. Accordingly, the Company received net proceeds of $250 and issued 50 shares of our common stock.

Equity Grant to non-executive employees

On March 7, 2014, our non-executive employees received 5,025 shares of our common stock pursuant to the terms of the non-executive equity grant. These shares represent 20% of the equity grant to non-executive employees that immediately vested but had not been issued as of January 31, 2014. (See Footnote 10: Commitments and Contingencies, Stock Awards). Accordingly, the Company recorded stock compensation expense of $20,250 during the quarter (representing the aggregate value of total shares earned) and issued 3,685 shares (on a net basis after employee payroll taxes) of our common stock during March 2014.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)

3 Months Ended

Jan. 31, 2014

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation - Unaudited Interim Financial Information

Use of Estimates, Policy [Policy Text Block]

Estimates

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

	As of January 31,
	2014		2013
Warrants		4,360,441		1,001,236
Stock Options		467,923		355,890
Convertible Debt (using the if-converted method)		3,354		390,566
Total		4,831,718		1,747,692

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock Based Compensation

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables)

3 Months Ended

Jan. 31, 2014

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.

	As of January 31,
	2014		2013
Warrants		4,360,441		1,001,236
Stock Options		467,923		355,890
Convertible Debt (using the if-converted method)		3,354		390,566
Total		4,831,718		1,747,692

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Jan. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consists of the following:

	January 31, 2014 (Unaudited)		October 31, 2013
Laboratory Equipment	$	333,727	$	309,132
Accumulated Depreciation		(235,650)		(228,747)
Net Property and Equipment	$	98,077	$	80,385

INTANGIBLE ASSETS (Tables)

3 Months Ended

Jan. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

The following is a summary of intangible assets as of the end of the following fiscal periods:

	January 31, 2014 (Unaudited)		October 31, 2013
License	$	651,992	$	651,992
Patents		2,708,970		2,696,543
Total intangibles		3,360,962		3,348,535
Accumulated Amortization		(861,918)		(819,984)
Intangible Assets	$	2,499,044	$	2,528,551

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated amortization expense for the next five years is as follows:

Year ended October 31,

2014 (Remaining)		125,500
2015		167,500
2016		167,500
2017		167,500
2018		167,500

ACCRUED EXPENSES: (Tables)

3 Months Ended

Jan. 31, 2014

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

The following table represents the major components of accrued expenses:

	January 31, 2014		October 31,
	(Unaudited)		2013
Salaries and Other Compensation	$	721,672	$	752,248
Consultants		2,000		2,000
Legal		15,000		15,000
Withholding Taxes Payable		185,585		-
Share Purchase		100,012		100,012
	$	1,024,269	$	869,260

DERIVATIVE INSTRUMENTS (Tables)

3 Months Ended

Jan. 31, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule Of Warrants Activity [Table Text Block]

A summary of changes in warrants for the three months ended January 31, 2014 is as follows:

	Number of	Weighted-Average
	Warrants	Exercise Price
Outstanding Warrants at October 31, 2013:	4,265,262	$	6.71
Issued	101,704	$	5.58
Exercised	-		-
Expired	(6,525)	$	21.25
Outstanding Warrants at January 31, 2014	4,360,441	$	6.66

Schedule Of Share Based Compensation Of Fair Value Of Options Using Black Scholes Option Pricing Model [Table Text Block]

In fair valuing the warrant liability, at January 31, 2014 and October 31, 2013, the Company used the following inputs in its BSM Model:

		01/31/2014			10/31/2013

Exercise Price:	$	2.76-21.25		$	2.76-21.25

Stock Price	$	4.49		$	3.74

Expected term:		41-1203 days			61-1371 days

Volatility %		91%-186	%		99%-186	%

Risk Free Rate:		.035%-.69	%		.035%-.94	%

STOCK OPTIONS: (Tables)

3 Months Ended

Jan. 31, 2014

Equity [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of changes in the stock option plan for three months ended January 31, 2014 is as follows:

	Number of		Weighted-Average
	Options		Exercise Price
Outstanding at October 31, 2013:		467,923	$	15.86
Granted		-	$	-
Exercised		-	$	-
Expired		-	$	-
Outstanding at January 31, 2014		467,923	$	15.86
Vested and Exercisable at January 31, 2014		403,567	$	16.22

COMMITMENTS AND CONTINGENCIES : (Tables)

3 Months Ended

Jan. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule Of Allocation Of Base Salary [Table Text Block]

The allocation between the cash and equity components of each Executive’s base salary is as follows:

	% of base salary	% of base salary
Executive	in cash	in stock
Daniel J. O’Connor	75.0	25.0
Gregory T. Mayes, III	92.5	7.5
Mark J. Rosenblum	92.5	7.5
Robert G. Petit	91.5	8.5
Chris L. French	95.0	5.0

FAIR VALUE (Tables)

3 Months Ended

Jan. 31, 2014

Fair Value [Line Items]

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following table provides the liabilities carried at fair value measured on a recurring basis as of January 31, 2014:

January 31, 2014	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from October 2012 through August 2017	$	-	$	$	516,268	$	516,268

October 31, 2013	Level 1		Level 2	Level 3		Total

Common stock warrant liability, warrants exercisable at $2.76 - $21.25 from October 2012 through August 2017	$	-	$	$	646,734	$	646,734

Common Stock Warrant Liability [Member]

Fair Value [Line Items]

Fair Value, Instruments Classified In Shareholders' Equity Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Common stock warrant liability:

	January 31, 2014 (Unaudited)
Beginning balance: October 31, 2013	$	646,734
Issuance of additional warrants due to anti-dilution provisions		1,482
Change in fair value		(131,948)

Balance at January 31, 2014	$	516,268

ORGANIZATION (Details Textual) $ in Millions	1 Months Ended
ORGANIZATION (Details Textual) $ in Millions	Oct. 31, 2013 USD ($)
Public Offering [Member]
Organization [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued	$ 24

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details) - shares	3 Months Ended
	Jan. 31, 2014	Jan. 31, 2013
Summary Of Significant Accounting Policies And Basis of Presentation [Line Items]
Total	4,831,718	1,747,692
Warrant [Member]
Summary Of Significant Accounting Policies And Basis of Presentation [Line Items]
Total	4,360,441	1,001,236
Employee Stock Option [Member]
Summary Of Significant Accounting Policies And Basis of Presentation [Line Items]
Total	467,923	355,890
Convertible Debt Securities [Member]
Summary Of Significant Accounting Policies And Basis of Presentation [Line Items]
Total	3,354	390,566

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Textual) $ in Millions	3 Months Ended
	Jan. 31, 2014 USD ($)
Summary Of Significant Accounting Policies And Basis of Presentation [Line Items]
Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure	$ 15.2

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jan. 31, 2014	Oct. 31, 2013
Property And Equipment [Line Items]
Laboratory Equipment	$ 333,727	$ 309,132
Accumulated Depreciation	(235,650)	(228,747)
Net Property and Equipment	$ 98,077	$ 80,385

PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	3 Months Ended		143 Months Ended
PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014
Property And Equipment [Line Items]
Depreciation expense	$ 6,903	$ 4,592	$ 235,650

INTANGIBLE ASSETS (Details) - USD ($)	Jan. 31, 2014	Oct. 31, 2013
Finite-Lived Intangible Assets [Line Items]
License	$ 651,992	$ 651,992
Patents	2,708,970	2,696,543
Total intangibles	3,360,962	3,348,535
Accumulated Amortization	(861,918)	(819,984)
Intangible Assets	$ 2,499,044	$ 2,528,551

INTANGIBLE ASSETS (Details 1)	Oct. 31, 2013 USD ($)
Amortization Expense Per Equivalent Unit of Production or Per Dollar of Gross Revenue [Line Items]
2014 (Remaining)	$ 125,500
2015	167,500
2016	167,500
2017	167,500
2018	$ 167,500

INTANGIBLE ASSETS (Details Textual) - USD ($)	3 Months Ended		143 Months Ended
INTANGIBLE ASSETS (Details Textual) - USD ($)	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization expense of intangibles	$ 41,934	$ 38,703	$ 943,913
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Patents Expirations	2014
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Patents Expirations	2023

ACCRUED EXPENSES: (Details) - USD ($)	Jan. 31, 2014	Oct. 31, 2013
Accrued Expenses [Line Items]
Salaries and Other Compensation	$ 721,672	$ 752,248
Consultants	2,000	2,000
Legal	15,000	15,000
Withholding Taxes Payable	185,585	0
Share Purchase	100,012	100,012
Accrued Liabilities, Current	$ 1,024,269	$ 869,260

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE (Details Textual) - USD ($)	Jan. 31, 2014	Oct. 31, 2013
Junior Convertible Subordinated Convertible Notes [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current	$ 63,000	$ 63,000

NOTES PAYABLE- FORMER OFFICER: (Details Textual) - USD ($)		3 Months Ended		143 Months Ended
	Feb. 04, 2014	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014	Oct. 31, 2013
Schedule Of Notes Payable officer [Line Items]
Notes Payable and Interest Payable Current		$ 165,097		$ 165,097	$ 163,132
Repayments Of Related Party Debt		0	$ 0	$ 1,323,833
Moore Notes [Member]
Schedule Of Notes Payable officer [Line Items]
Interest Expense, Debt		$ 5,000	$ 9,500
Notes Payable and Interest Payable Current					$ 163,132
Moore Notes [Member] \| Subsequent Event [Member]
Schedule Of Notes Payable officer [Line Items]
Repayments Of Related Party Debt	$ 168,280

DERIVATIVE INSTRUMENTS (Details)	3 Months Ended
DERIVATIVE INSTRUMENTS (Details)	Jan. 31, 2014 $ / shares shares
Schedule Of Warrants Activity [Line Items]
Outstanding Warrants at October 31, 2013 \| shares	4,265,262
Issued, Number of Warrants \| shares	101,704
Exercised, Number of Warrants \| shares	0
Expired, Number of Warrants \| shares	(6,525)
Outstanding Warrants at January 31, 2014 \| shares	4,360,441
Outstanding Warrants Exercise Price at October 31, 2013 \| $ / shares	6.71
Issued, Weighted-Average Exercise Price \| $ / shares	$ 5.58
Exercised, Weighted-Average Exercise Price \| $ / shares	0
Expired, Weighted-Average Exercise Price \| $ / shares	$ 21.25
Outstanding Warrants Exercise Price at January 31, 2014 \| $ / shares	6.66

DERIVATIVE INSTRUMENTS (Details 1) - $ / shares	3 Months Ended	12 Months Ended
DERIVATIVE INSTRUMENTS (Details 1) - $ / shares	Jan. 31, 2014	Oct. 31, 2013
Class of Warrant or Right [Line Items]
Stock Price	$ 4.49	$ 3.74
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price:	$ 2.76	$ 2.76
Expected term:	41 days	61 days
Volatility %	91.00%	99.00%
Risk Free Rate:	0.035%	0.035%
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price:	$ 21.25	$ 21.25
Expected term:	1203 days	1371 days
Volatility %	186.00%	186.00%
Risk Free Rate:	69.00%	94.00%

DERIVATIVE INSTRUMENTS (Details Textual)	3 Months Ended		12 Months Ended
DERIVATIVE INSTRUMENTS (Details Textual)	Jan. 31, 2014 USD ($) Warrants $ / shares shares	Jan. 31, 2013 USD ($)	Oct. 31, 2013 USD ($) $ / shares shares
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	4,360,441		4,265,262
Derivative Liability, Fair Value, Gross Liability \| $			$ 647,000
Warrants Subject To Anti Dilution Provisions \| shares	561,000		565,000
Derivative, Gain (Loss) on Derivative, Net, Total \| $	$ 132,000	$ 2,900,000
Fair Value Adjustment of Warrants \| $	$ 500,000		$ 600,000
Warrants Issued, Exercise Price	$ 5.58
Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	2.76		$ 2.76
Anti Dilution Provisions Additional Warrants Exercise Price	7.50
Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	21.25		$ 21.25
Anti Dilution Provisions Additional Warrants Exercise Price	$ 9.16
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	283,000		287,000
Exercise of warrants \| $	$ 278,000		$ 278,000
Derivative Liability, Fair Value, Gross Liability \| $	$ 516,000		$ 565,000
Warrant Liability [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	4,400,000		4,300,000
Derivative Liability, Fair Value, Gross Liability \| $	$ 600,000		$ 600,000
Warrant Equity [Member]
Class of Warrant or Right [Line Items]
Exercise of warrants \| $	$ 278,329
Warrants With Anti Dilution Provisions [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.16		$ 9.26
Warrants Subject To Anti Dilution Provisions \| shares	204,000		203,000
Anti Dilution Provisions Additional Warrants Issuable \| shares	1,700
Anti Dilution Provisions Additional Warrants Exercise Price	$ 25.00
Warrants With Anti Dilution Provisions [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Probability Of Exercise Of Additional Warrants At Exercise Price One	40.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two	50.00%
Warrants With Anti Dilution Provisions [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Probability Of Exercise Of Additional Warrants At Exercise Price One	50.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two	60.00%
Warrant [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.76
Warrant [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 21.25
Equity Warrants [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding \| shares	4,400,000		4,400,000
Derivative Liability, Fair Value, Gross Liability \| $	$ 3,800,000		$ 3,800,000
Warrants Issued, Exercise Price	$ 5.52
Issuance Of Warrants \| Warrants	100,000
warrants expire period	2018

STOCK OPTIONS: (Details)	3 Months Ended
STOCK OPTIONS: (Details)	Jan. 31, 2014 $ / shares shares
Schedule Of Stock Options [Line Items]
Outstanding at October 31, 2013, Number of Shares \| shares	467,923
Granted, Number of Shares \| shares	0
Exercised, Number of Shares \| shares	0
Expired, Number of Shares \| shares	0
Outstanding at January 31, 2014, Number of Shares \| shares	467,923
Vested and Exercisable at January 31, 2014, Number of Shares \| shares	403,567
Outstanding at October 31, 2013, Weighted-Average Exercise Price \| $ / shares	$ 15.86
Granted, Weighted-Average Exercise Price \| $ / shares	0
Exercised, Weighted-Average Exercise Price \| $ / shares	0
Expired, Weighted Average Exercise Price \| $ / shares	0
Outstanding at January 31, 2014, Weighted-Average Exercise Price \| $ / shares	15.86
Vested and Exercisable at January 31, 2014, Weighted-Average Exercise Price \| $ / shares	$ 16.22

STOCK OPTIONS: (Details Textual) - USD ($)	3 Months Ended		143 Months Ended
STOCK OPTIONS: (Details Textual) - USD ($)	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014
Schedule Of Stock Options [Line Items]
Vested & Exercisable Weighted Average Remaining Contractual Life In Years	10 months 13 days
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value		$ 0
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	$ 947,000		$ 947,000
Employee Stock Ownership Plan (ESOP), Compensation Expense	257,486	263,000
Share-Based Compensation	1,602,423	369,923	11,128,461
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	6,880		$ 6,880
General and Administrative Expense [Member]
Schedule Of Stock Options [Line Items]
Share-Based Compensation	167,106	153,000
Research and Development Expense [Member]
Schedule Of Stock Options [Line Items]
Share-Based Compensation	$ 90,380	$ 110,000

COMMITMENTS AND CONTINGENCIES : (Details)	3 Months Ended
COMMITMENTS AND CONTINGENCIES : (Details)	Jan. 31, 2014
Daniel J. O'Connor [Member]
Commitments And Contingencies [Line Items]
Percentage of base salary in cash	75.00%
Percentage of base salary in stock	25.00%
Gregory T. Mayes, III [Member]
Commitments And Contingencies [Line Items]
Percentage of base salary in cash	92.50%
Percentage of base salary in stock	7.50%
Mark J. Rosenblum [Member]
Commitments And Contingencies [Line Items]
Percentage of base salary in cash	92.50%
Percentage of base salary in stock	7.50%
Robert G. Petit [Member]
Commitments And Contingencies [Line Items]
Percentage of base salary in cash	91.50%
Percentage of base salary in stock	8.50%
Chris L. French [Member]
Commitments And Contingencies [Line Items]
Percentage of base salary in cash	95.00%
Percentage of base salary in stock	5.00%

COMMITMENTS AND CONTINGENCIES : (Details Textual)						1 Months Ended					3 Months Ended
COMMITMENTS AND CONTINGENCIES : (Details Textual)	Mar. 07, 2014 USD ($)	Feb. 05, 2014 USD ($)	Feb. 04, 2014 USD ($)	Nov. 14, 2013 USD ($)	Mar. 06, 2013 USD ($)	Dec. 31, 2013 USD ($) shares	Dec. 27, 2013 USD ($)	Oct. 31, 2013 USD ($) $ / shares shares	Oct. 22, 2013 USD ($) shares	Aug. 19, 2013 USD ($) $ / Warrants shares	Jan. 31, 2014 USD ($) $ / shares shares	Dec. 18, 2013 shares	Sep. 27, 2013 shares
Commitments And Contingencies [Line Items]
Common stock, shares issued \| shares								13,719,861			14,009,475
Proceeds From Net Operating Losses											$ 625,563
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares								6.71			6.66
Accounts Payable, Current								$ 3,841,771			$ 2,305,859
Notes Payable and Interest Payable Current								$ 163,132			$ 165,097
Executives [Member] \| Subsequent Event [Member]
Commitments And Contingencies [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 4,017
Non Executive Employees [Member] \| Common Stock [Member]
Commitments And Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period \| shares											1,675
Non Executive Employees [Member] \| Stock Bonus Award [Member]
Commitments And Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value						$ 5,025
Non Executive Employees [Member] \| Restricted Stock Units (RSUs) [Member]
Commitments And Contingencies [Line Items]
Percentage Of Stock Units Vested Immediately						20.00%
Percentage Of Stock Units Remaining Unvested						80.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance \| shares								81,000
Percentage Of Stock Units Vested By Third Anniversary Of Grant Date						100.00%
Share Based Compensation Arrangement By Share Based Payments Award, Stock Units Granted, Grant Date Fair Value						$ 101,250
Percentage Of Stock Units Vested Immediately						20.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value						$ 20,250					$ 7,520
Non Executive Employees [Member] \| Subsequent Event [Member]
Commitments And Contingencies [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 5,025
Percentage Of Stock Units Vested Immediately	20.00%
Percentage Of Stock Units Vested Immediately	20.00%
Executive Officer [Member] \| Stock Bonus Award [Member]
Commitments And Contingencies [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross \| shares						105,000
Common Stock, Capital Shares Reserved for Future Issuance \| shares						525,000
Percentage Of Stock Units Vested Immediately						20.00%
Percentage Of Stock Units Vested Immediately						20.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value											35,000
Stock Issued During Period, Value, Restricted Stock Award, Gross						$ 423,150
Fair Value Of Bonus Shares issued						$ 129,000
Bonus Shares issued \| shares						31,846
Executive Officer [Member] \| Restricted Stock Units (RSUs) [Member]
Commitments And Contingencies [Line Items]
Percentage Of Stock Units Remaining Unvested						80.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance \| shares						420,000
Percentage Of Stock Units Vested By Third Anniversary Of Grant Date						100.00%
Executive Officer [Member] \| Subsequent Event [Member] \| Common Stock [Member]
Commitments And Contingencies [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Gross											$ 18,000
Stock Issued During Period, Shares, Share-based Compensation, Gross \| shares											4,017
Stock Issued During Period, Shares, Share-based Compensation, Forfeited \| shares											3,134
Non Employee Director [Member] \| Restricted Stock Units (RSUs) [Member]
Commitments And Contingencies [Line Items]
Percentage Of Stock Units Vested By Third Anniversary Of Grant Date						100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period \| shares						50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term						3 years
Mr Moore [Member]
Commitments And Contingencies [Line Items]
Repayments of Notes Payable			$ 168,280						$ 100,000
Debt Conversion, Converted Instrument, Amount									$ 162,132
Debt Conversion, Converted Instrument, Shares Issued \| shares									40,783
Debt Conversion, Converted Instrument, Warrants or Options Issued \| shares									20,392
Debt Conversion Converted Instrument Warrants Exercise Price \| $ / shares								$ 5.00
Notes Payable and Interest Payable Current								$ 163,132
Mr Moore [Member] \| Restricted Stock Units (RSUs) [Member]
Commitments And Contingencies [Line Items]
Percentage Of Stock Units Vested By Third Anniversary Of Grant Date						100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period \| shares						37,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term						3 years
Mr Moore [Member] \| Consulting Agreement [Member]
Commitments And Contingencies [Line Items]
Consultancy Fee										$ 350,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross \| shares										37,500
Separation Agreement [Member]
Commitments And Contingencies [Line Items]
General Release Agreement					$ 275,000
Pennsylvania [Member]
Commitments And Contingencies [Line Items]
Stock issued											$ 28,468
Licensing Agreement Expenses								325,000			127,000
Pennsylvania [Member] \| Licensing Agreements [Member]
Commitments And Contingencies [Line Items]
Accounts Payable, Current											$ 306,000
Maxim Group LLC [Member]
Commitments And Contingencies [Line Items]
Common stock, shares issued \| shares													158,385
Loss Contingency, Damages Sought, Value				$ 484,710
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares										30,154
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / Warrants										4.90
Common Stock Shares Cancelled \| shares												158,385	158,385
Additional Consideration Paid								$ 150,000
Loss Contingency, Damages Paid, Value							$ 285,000

SHAREHOLDERS' EQUITY (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
SHAREHOLDERS' EQUITY (Details Textual) - USD ($)	Feb. 28, 2014	Jan. 31, 2014
Shareholders Equity [Line Items]
Number Of Shares Issued To Terminate Purchase Agreement		7,080
Global BioPharma Inc [Member] \| Stock Purchase Agreement [Member]
Shareholders Equity [Line Items]
Proceeds from Issuance or Sale of Equity		$ 400,000
Global BioPharma Inc [Member] \| Stock Purchase Agreement [Member] \| Subsequent Event [Member]
Shareholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues	108,724

FAIR VALUE (Details) - USD ($)	Jan. 31, 2014	Oct. 31, 2013
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable	$ 516,268	$ 646,734
Fair Value, Inputs, Level 1 [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable	$ 516,268	$ 646,734

FAIR VALUE (Details 1) - Common Stock Warrant Liability [Member]	3 Months Ended
	Jan. 31, 2014 USD ($)
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance: October 31, 2013	$ 646,734
Issuance of additional warrants due to anti-dilution provisions	1,482
Change in fair value	(131,948)
Balance at January 31, 2014	$ 516,268

FAIR VALUE (Details Textual) - $ / shares	Jan. 31, 2014	Oct. 31, 2013
Minimum [Member]
Fair Value [Line Items]
Exercise Price	$ 2.76	$ 2.76
Maximum [Member]
Fair Value [Line Items]
Exercise Price	$ 21.25	$ 21.25

SUBSEQUENT EVENTS (Details Textual) - USD ($)			1 Months Ended		3 Months Ended		143 Months Ended
SUBSEQUENT EVENTS (Details Textual) - USD ($)	Mar. 07, 2014	Feb. 05, 2014	Feb. 28, 2014	Feb. 21, 2014	Jan. 31, 2014	Jan. 31, 2013	Jan. 31, 2014
Subsequent Event [Line Items]
Share-Based Compensation					$ 1,602,423	$ 369,923	$ 11,128,461
Subsequent Event [Member]
Subsequent Event [Line Items]
Number Of Warrants Exercised				50
Exercise Price Of Warrants Exercised			$ 5.00
Proceeds From Exercise Of Warrants				$ 250
Stock Issued During Period Upon Exercise Of Warrants				50
Subsequent Event [Member] \| Executives [Member]
Subsequent Event [Line Items]
Number Of Shares Issued To Executives On Net Basis After Employee Payroll Taxes		3,134
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 4,017
Share-Based Compensation		$ 18,000
Subsequent Event [Member] \| Non Executive Employees [Member]
Subsequent Event [Line Items]
Number Of Shares Issued To Executives On Net Basis After Employee Payroll Taxes	3,685
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 5,025
Percentage Of Stock Units Vested Immediately	20.00%
Share-Based Compensation	$ 20,250

STOCK OPTIONS: (Details)	3 Months Ended
STOCK OPTIONS: (Details)	Jan. 31, 2014 $ / shares shares
Schedule Of Stock Options [Line Items]
Outstanding at October 31, 2013, Number of Shares \| shares	467,923
Granted, Number of Shares \| shares	0
Exercised, Number of Shares \| shares	0
Expired, Number of Shares \| shares	0
Outstanding at January 31, 2014, Number of Shares \| shares	467,923
Vested and Exercisable at January 31, 2014, Number of Shares \| shares	403,567
Outstanding at October 31, 2013, Weighted-Average Exercise Price \| $ / shares	$ 15.86
Granted, Weighted-Average Exercise Price \| $ / shares	0
Exercised, Weighted-Average Exercise Price \| $ / shares	0
Expired, Weighted Average Exercise Price \| $ / shares	0
Outstanding at January 31, 2014, Weighted-Average Exercise Price \| $ / shares	15.86
Vested and Exercisable at January 31, 2014, Weighted-Average Exercise Price \| $ / shares	$ 16.22